|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
154,660,000 |
Market
Cap: |
156.21(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.429 - $1.75 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
165,799 |
218,930 |
354,372 |
Total Sell Value |
$0 |
$124,385 |
$172,782 |
$411,912 |
Total People Sold |
0 |
4 |
5 |
6 |
Total Sell Transactions |
0 |
16 |
19 |
41 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Norry Elliot |
Chief Medical Officer |
|
2023-01-17 |
4 |
S |
$1.86 |
$4,011 |
D/D |
(2,159) |
3,491 |
|
33% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2023-01-17 |
4 |
S |
$1.86 |
$18,686 |
D/D |
(10,057) |
13,351 |
|
33% |
|
Norry Elliot |
Chief Medical Officer |
|
2023-01-12 |
4 |
S |
$1.71 |
$12,708 |
D/D |
(7,449) |
12,191 |
|
33% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2023-01-12 |
4 |
S |
$1.71 |
$8,484 |
D/D |
(4,973) |
8,121 |
|
33% |
|
Lunger John |
Chief Patient Supply Officer |
|
2023-01-12 |
4 |
S |
$1.71 |
$8,484 |
D/D |
(4,973) |
8,121 |
|
33% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2023-01-12 |
4 |
S |
$1.71 |
$32,010 |
D/D |
(18,763) |
24,882 |
|
33% |
|
Norry Elliot |
Chief Medical Officer |
|
2023-01-11 |
4 |
S |
$1.75 |
$6,713 |
D/D |
(3,843) |
6,270 |
|
28% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2023-01-11 |
4 |
S |
$1.75 |
$6,713 |
D/D |
(3,843) |
6,270 |
|
28% |
|
Lunger John |
Chief Patient Supply Officer |
|
2023-01-11 |
4 |
S |
$1.75 |
$6,713 |
D/D |
(3,843) |
6,270 |
|
28% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2023-01-11 |
4 |
S |
$1.75 |
$22,782 |
D/D |
(13,042) |
17,298 |
|
28% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2023-01-04 |
4 |
S |
$1.69 |
$8,594 |
D/D |
(5,073) |
6,631 |
|
22% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2023-01-04 |
4 |
S |
$1.69 |
$6,071 |
D/D |
(3,584) |
5,781 |
|
22% |
|
Lunger John |
Chief Patient Supply Officer |
|
2023-01-04 |
4 |
S |
$1.69 |
$1,863 |
D/D |
(1,100) |
1,725 |
|
22% |
|
Norry Elliot |
Chief Medical Officer |
|
2023-01-04 |
4 |
S |
$1.69 |
$1,484 |
D/D |
(876) |
1,361 |
|
22% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2022-09-01 |
4 |
S |
$1.97 |
$4,993 |
D/D |
(2,536) |
3,316 |
|
3% |
|
Piccina Cintia |
Chief Commercial Officer |
|
2022-08-01 |
4 |
S |
$1.77 |
$37,314 |
D/D |
(21,040) |
34,824 |
|
14% |
|
Lunger John |
Chief Patient Supply Officer |
|
2022-08-01 |
4 |
S |
$1.77 |
$5,290 |
D/D |
(2,983) |
4,829 |
|
14% |
|
Lunger John |
Chief Patient Supply Officer |
|
2022-07-05 |
4 |
S |
$1.68 |
$3,311 |
D/D |
(1,973) |
3,104 |
|
-51% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2022-06-27 |
4 |
S |
$1.63 |
$4,176 |
D/D |
(2,562) |
3,290 |
|
6% |
|
Wood Gavin |
Chief Financial Officer |
|
2022-05-20 |
4 |
B |
$0.29 |
$11,326 |
D/D |
39,000 |
96,000 |
2.74 |
-34% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2022-01-18 |
4 |
S |
$3.19 |
$35,416 |
D/D |
(11,096) |
12,312 |
|
52% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2022-01-18 |
4 |
S |
$3.19 |
$13,942 |
D/D |
(4,368) |
7,336 |
|
52% |
|
Lunger John |
Chief Patient Supply Officer |
|
2022-01-18 |
4 |
S |
$3.19 |
$13,942 |
D/D |
(4,368) |
7,336 |
|
52% |
|
Norry Elliot |
Chief Medical Officer |
|
2022-01-18 |
4 |
S |
$3.19 |
$6,770 |
D/D |
(2,121) |
3,529 |
|
52% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2022-01-12 |
4 |
S |
$3.54 |
$7,967 |
D/D |
(2,248) |
3,754 |
|
56% |
|
234 Records found
|
|
Page 2 of 10 |
|
|